On Thursday, February 16, 2023, Kevin Conroy, chairman and CEO of Exact Sciences keynoted the TGen’s Arizona Bioscience Impact breakfast and shared his belief in the powerful impact of early detection in saving lives and improving cancer care. He also introduced the audience to Exact Sciences newest diagnostic innovation – OncoExTra.Continue reading
Category Archives: AZBio News
ASU’s Biodesign Institute blazes new research trails
Stream of funding spurs advances in human health:
Arizona State University Biodesign Institute researchers have received three significant new grants, advancing knowledge of digestive proteins in the human gut, toxic exposure to fungi during childhood and long-term vaccine effectiveness. Continue reading
reimagine Health Research Symposium Focuses on Big Data’s Role in Transforming Care
Fifth Annual Symposium welcomed experts, who shared how big data and precision medicine are set to markedly improve clinical outcomesContinue reading
Game Changer: The Arizona Health Innovation Trust Fund
Established in 2022, the Arizona Health Innovation Trust Fund (AHIT) is designed to help Arizona become home to a top-ten life science sector by helping to bridge the “valley of death.” During the 2023 legislative session, our elected leaders have the opportunity to make the investment that will capitalize the AHIT. Continue reading
First-of-its-kind instrument officially ushers in new era of X-ray science
“This marks the beginning of a new era of science with compact accelerator-based X‑ray sources,” said Robert Kaindl, who directs ASU’s Compact X-ray Free Electron Laser (CXFEL) Labs at the Biodesign Institute and is a professor in the Department of Physics. “The CXLS provides hard X-ray pulses with high flux, stability and ultrashort durations, in a very compact footprint. This way, matter can be resolved at its fundamental scales in space and time, enabling new discoveries across many fields — from next-generation materials for computing and information science, to renewable energy, biomolecular dynamics, drug discovery and human health.”Continue reading
RESI Boston June 2023
Life Science Nation is hosting a RESI conference which will be hybrid, June 5-7th. It will take place onsite on Monday June 5th at the Westin Copley Place from 8am – 5pm Eastern Time, and digitally on the 6th and 7th on the Partnering Platform. LSN is offering Arizona Bioindustry Association (AZBio) members a discounted registration for their early-stage startupsContinue reading
FAST Program Applications
FEDERAL & STATE TECHNOLOGY PARTNERSHIP PROGRAM
The Small Business Administration’s Federal and State Technology (FAST) Partnership Program is designed to support programs that advance innovative, technology-driven small businesses. The Arizona Commerce Authority has partnered with the Small Business Administration (SBA) to facilitate the FAST program in Arizona.Continue reading
Exact Sciences and PGA Tour Champions Extend Partnership Through 2027
Tucson, Ariz. (February 1, 2023) – The PGA TOUR Champions, the Tucson Conquistadores, the First Tee Tucson, and Exact Sciences, the maker of Cologuard®, announced today that the Madison, Wisconsin-based company will now be the presenting sponsor of the Cologuard Classic. The announcement also extends Cologuard’s title sponsorship through the 2027 season. The 2023 Cologuard Classic by Exact Sciences will take place at the Omni Tucson National Resort from February 27th through March 5th and will have a $2.2 million purse, with $330,000 to the winner.Continue reading
Aqualung Therapeutics Concludes ALT-100 Antibody (mAb) Dosing in Its P1a Study with no Reported SAE’s. Will Engage FDA for Clearance of the P2a PUERTA Study in Moderate/Severe Acute Respiratory Distress Syndrome (ARDS) Patients
TUCSON, AZ / ACESSWIRE / January 31, 2023 / Aqualung Therapeutics, an early stage immunotherapeutics company with a novel anti-inflammatory and anti-fibrotic therapeutic platform for life-threatening unchecked inflammation/fibrosis, today announced that it has engaged Novotech, a leading Asia Pacific centered, full-service contract research organization (“CRO”) in the Asia-Pacific, United States and Europe, for its upcoming Phase 2a PUERTA clinical trial utilizing the humanized ALT-100 mAb. Aqualung currently plans to initiate its Phase 2a clinical trial in Australia starting in Q2 2023. The study will enroll moderate/severe ARDS subjects in hospital locations in Australia as well at multiple sites in the United States.Continue reading